Presentation is loading. Please wait.

Presentation is loading. Please wait.

I I talian talian S S arcoma arcoma G G roup roup Started June 1997

Published byClarisse Lacroix Modified over 5 years ago

Similar presentations

Presentation on theme: "I I talian talian S S arcoma arcoma G G roup roup Started June 1997"— Presentation transcript:

1 I I talian talian S S arcoma arcoma G G roup roup Started June 1997
I I talian talian Started June 1997 S S arcoma arcoma G G roup roup Formalized October 2002

2 Italian Sarcoma Group 210 members 68 Centers • 14 National Institutes
BELGIUM 68 Centers • 14 National Institutes • 14 Universities • 34 Pubblic Hospitals • 6 Private Hospitals 1 1 1 8 1 1 1 1 1 1 1 10 1 1 3 1 2 1 1 1 1 1 6 2 1 1 1 1 1 3 1 1 1 1 2 1 5 1 210 members at november 2005 2

3 Osteosarcoma Protocols
Italian Sarcoma Group Osteosarcoma Protocols • ISG/SSG I (localized disease): 3/ /2001, 182 pts JCO 2005 • ISG/SSG II (metastatic disease): 3/ /2002, 57 pts ASCO 2005 • ISG/OS I (localized disease) activated 4/2001, 212 pts • EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 79 pts • High risk (relapsed patients) activated 12/2002, 28 pts

4 Ewing’s Sarcoma Protocols
Italian Sarcoma Group Ewing’s Sarcoma Protocols • ISG/SSG III (standard risk) activated 6/99, 240 pts • ISG/SSG IV (high risk) activated 6/99, 74 pts ASCO 2005 • ISG/AIEOP (very high risk) activated 12/2002, 19 pts • Relapsed Patients activated 12/2002, 22 pts

5 Adult soft tissue sarcomas - Protocols
Italian Sarcoma Group Adult soft tissue sarcomas - Protocols • ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk localized disease) with Spanish Group (222 pts) • ISG/STS 03/02 (neodjuvant IFO+RT in retroperitoneal) (15 pts) • HD-IFX in continuous infusion (2nd-4th line) • Gemcytabine in leiomyosarcomas (2nd-3rd line) • Paclitaxel in angiosarcomas (2a line) • Miniallogenic Transplant (advanced disease, responsive patients) • Imatinib in advanced chordoma (35 pts)

6 GIST Protocols • GIOTTO (observational, , in collaboration with Novartis) (>700 pts) • REGISTER (retrospective, histhological) • (adjuvant Imatinib), intergroup with EORTC • Institutions from the ISG participated in the following studies on new agents in GIST: SU11248 (international) CLOSED • PTK787 (international) • AMG706 (international)

7 Italian Population : 57 Millions
Italian Sarcoma Group Possible accrual Italian Population : 57 Millions Osteosarcoma: 90/120 (75%!) Ewing’s Sarcoma: 50/60 (80%!) Adult soft tissue sarcomas: 700/1400 (50%?)

8 Started January 1st, 2005 - 3 year project Website: WWW.PROTHETS.ORG
Total grant: ,00 Euro Website:

9 Dr. Piero Picci (Co-ordinator)
*Partner 1 Istituti Ortopedici Rizzoli (IOR, Italy) Dr.ssa Katia Scotlandi *Partner 2 Institut National de la Santé et de la Recherche Médicale (INSERM, France) Pr. Alain Bernard *Partner 3 Laboratory for Experimental Orthopaedic Research (UKM, Germany) Dr. Frans van Valen *Partner 4 University of Helsinki (UH.DMG, Finland) Prof. Sakari Knuutila *Partner 5 Department of Pathology, University of Valencia (UVEG, Spain) Prof. Antonio Lombart-Bosch *Partner 6 Children´s Cancer Research Institute (CCRI, Austria) Prof. Dr. Heinrich Kovar *Partner 7 Université Paris 7 Denis-Diderot (UP7 DD, France) Dr. Bernard Perbal *Partner 8 Centre National de la Recherche Scientifique (CNRS, France) Dr. Claude Malvy *Partner 9 Belozersky Inst. of Physico-Chemical Biology of the Moscow State Univ. (BI.MSU) Dr.ssa Marina Gottikh *Partner 10 GenX Laboratories srl (GENX, Italy) Dr. Alessandro Borsatti *Partner 11 MABGENE S.A. (MABG, France) Agnès Leconte

10 PROTHETS - OBJECTIVES Prognostic factors: fusion transcripts, secondary cytogenetic and molecular alterations, CD99, IGF-IR, NOVH, erbB-2, TTF1 Targeted therapeutic approaches: EWS/FLI1, CD99, erbB-2, IGF-IR, TRAIL Genomic profiles for evaluation of tumor progression and response to chemotherapy

11 WP3: Prognostic relevance of selected promising predictive markers
87 primary or established cell lines 445 paraffin block material 145 frozen material 80 serum collected from ESFT pts 3 tissue arrays More than 200 inclusions for EM

12 Evaluation of prognostic value of new genes
GALS3BP HINT1 STOML2 CANX FVT1 RPS4Y1 Prognostic value in a very small clinical series: 36 primary untreated biopsies, homogenous for histology, checked for RNA quality Confirmatory studies: Protein analysis  Tissue Array Functional studies: in vitro siRNA silencing or forced expression

Download ppt "I I talian talian S S arcoma arcoma G G roup roup Started June 1997"

Similar presentations

Integration of Taxanes in the Management of Breast Cancer

Integration of Taxanes in the Management of Breast Cancer
Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.

Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
Rarer Sarcoma Subtypes Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Boston, MA.

Rarer Sarcoma Subtypes Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Boston, MA.
ACRIN 6687 A Phase 2, Multicenter Evaluation of 18 F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant.

ACRIN 6687 A Phase 2, Multicenter Evaluation of 18 F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant.
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross- match comparison in the EORTC Intergroup 62005 study.

Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross- match comparison in the EORTC Intergroup study.
2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!

2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.

Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.
These slides were released by the speaker for internal use by Novartis.

These slides were released by the speaker for internal use by Novartis.
Taiwan 2000 PETACC 3 ASCO 2009 Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC.

Taiwan 2000 PETACC 3 ASCO 2009 Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.

EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
SARC020 – EORTC 62091 TRUSTS – A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to.

SARC020 – EORTC TRUSTS – A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to.
SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.

SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME

SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
CLINICAL PRACTICE GUIDELINES Connective Tissue Oncology Society 2005 Meeting, Boca Raton Vivien Bramwell Chair, NCIC-CTG Sarcoma Committee Canadian Sarcoma.

CLINICAL PRACTICE GUIDELINES Connective Tissue Oncology Society 2005 Meeting, Boca Raton Vivien Bramwell Chair, NCIC-CTG Sarcoma Committee Canadian Sarcoma.
Heinrich & Corless Laboratories GIST Research Updates: May 2011.

Heinrich & Corless Laboratories GIST Research Updates: May 2011.
Paris- RP Reims Rennes Tours Marseille Montpellier Lyon Nice Lille Strasbourg Bordeaux Dijon Besançon Nantes Toulouse Poitiers Angers Nancy Caen Rouen.

Paris- RP Reims Rennes Tours Marseille Montpellier Lyon Nice Lille Strasbourg Bordeaux Dijon Besançon Nantes Toulouse Poitiers Angers Nancy Caen Rouen.
Therapeutic Targeting of EWS-FLI1: Small Molecule Protein-Protein Interaction Inhibitors Prevent Xenograft Growth Jeffrey Toretsky Department of Oncology.

Therapeutic Targeting of EWS-FLI1: Small Molecule Protein-Protein Interaction Inhibitors Prevent Xenograft Growth Jeffrey Toretsky Department of Oncology.

Similar presentations

Ads by Google